IN-VITRO ANTIBACTERIAL ACTIVITY OF THE NEW QUINOLONE BAY-Y3118 AGAINST CLINICAL ISOLATES

The in vitro antibacterial activity of the new fluoroquinolone Bay y31 18 against 609 clinical isolates was evaluated. Bay y3118 exhibited ac tivity against a broad spectrum of organisms, including Gram-negative bacilli, Gram-positive cocci, mycobacteria. The activity of Bay y3118 was often superior to that of other quinolones. Against Gram-negative bacilli its activity was similar to that of ceftriaxone, cefotaxime, c eftazidime and imipenem except for Serratia marcescens, Klebsiella pne umoniae, Enterobacter spp. and Xanthomonas maltophilia, where its acti vity was superior. Gentamicin and piperacillin sometimes were less act ive. Bay y3118 was active against a large number of Gram-positive cocc i. The fluoroquinolones tested were active against all the strains of Mycobacterium tuberculosis, but only Bay y3118 was effective against M ycobacterium avium.